Rocket Pharmaceuticals (RCKT) Reports Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: RCKT) | Delayed: 2.29 -0.02 (0.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.31 | 52 Week High | $ | |||
| Open | $2.27 | 52 Week Low | $ | |||
| Day High | $2.29 | P/E | N/A | |||
| Day Low | $2.17 | EPS | $ | |||
| Volume | 1,596,624 | |||||
